Trial Profile
A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2015
Price :
$35
*
At a glance
- Drugs PF 3654746 (Primary)
- Indications Narcolepsy; Somnolence
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Feb 2015 New trial record